Komori
Other Disclosures4890Tsubota Laboratory IncorporatedPharmaceuticals

A series of speaking engagements at ophthalmology-related conferences and symposia in countries around the world

The company's representative director and president spoke at ophthalmology-related conferences and symposia in China, the United States, South Korea and other countries in 2026, presenting research findings on myopia, dry eye and the mechanisms of tear secretion. Most recently, the president spoke at a conference held in Singapore on 5 September 2026.

Worth reading
48Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Announced details

Applicable field (uses covered by this announcement)

Myopia, dry eye, tear secretion, ophthalmology research

Launch date27 May 2026, 29 May 2026, 11 July 2026, 25 July 2026, 29 August 2026 and 5 September 2026 (all are presentation dates; 5 September was an actual presentation)
What the company reported numerically
Usage history

Multiple presentations were given in China, the United States, South Korea, Singapore and other countries in 2026

Relationship between the counterparty and the company
Tsubota Laboratory Incorporated4890
Relationship with the Company

The relationship is that the company's representative director and president spoke at conferences and symposia. Capital, personnel and business relationships: Not disclosed.

CounterpartyAsia Dry Eye Summit 2026Wenzhou University Optometry HospitalVision ChinaDry Eye Society of the Americas (DESA)2026 Qingdao Eye HospitalKorean Dry Eye Society (KDES)
Location (as indicated in this announcement)

Shinjuku-ku, Tokyo (head office)

Impact on Business Performance

The impact on business performance is Not disclosed

The company does not address Contract Value / Offering price.

Source (materials cited by the company)

Official URL for the Asia Dry Eye Summit 2026 (https://www.ades2026.com/)

Announced details
ItemDetails
CounterpartyAsia Dry Eye Summit 2026, Wenzhou University Optometry Hospital, Vision China, Dry Eye Society of the Americas (DESA), 2026 Qingdao Eye Hospital, Korean Dry Eye Society (KDES)
Relationship with the CompanyThe relationship is that the company's representative director and president spoke at conferences and symposia. Capital, personnel and business relationships: Not disclosed.
Launch date27 May 2026, 29 May 2026, 11 July 2026, 25 July 2026, 29 August 2026 and 5 September 2026 (all are presentation dates; 5 September was an actual presentation)
Applicable areaMyopia, dry eye, tear secretion, ophthalmology research
LocationShinjuku-ku, Tokyo (head office)
Usage historyMultiple presentations were given in China, the United States, South Korea, Singapore and other countries in 2026
Impact on Business PerformanceThe impact on business performance is Not disclosed
SourceOfficial URL for the Asia Dry Eye Summit 2026 (https://www.ades2026.com/)
Items this document does not state (10)
Names of Products / Services CoveredCounterparty overviewContract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocation scaleQuantitative Effects

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To expand its research network through academic exchanges with researchers and healthcare professionals in Japan and overseas, promote the practical application of research findings, and create new value that contributes to the health of people around the world.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
A series of speaking engagements at ophthalmology-related conferences and symposia in countries around the world | Tsubota Laboratory Incorporated (4890) timely disclosure | Komori